secwatch / observer
8-K filed May 11, 2026, 7:59 PM ET ticker LXEO CIK 0001907108
earnings confidence high sentiment positive materiality 0.75

Lexeo Therapeutics Q1 net loss $20.2M; cash $227.6M; LX2006 pivotal trial protocol submitted to FDA

Lexeo Therapeutics, Inc.

2026-Q1 EPS reported -$0.25
item 2.02item 8.01item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001193125-26-215674
form_type
8-K
ticker
LXEO
cik
0001907108
company_name
Lexeo Therapeutics, Inc.
filed_at
2026-05-11T23:59:59+00:00
discovered_at
2026-05-14T18:02:33.267929+00:00
generated_at
2026-05-14T19:00:25.526124+00:00
sec_items
["2.02", "8.01", "9.01"]
event_type
earnings
sentiment
positive
materiality_score
0.75
calibrated_materiality_score
0.75
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001193125-26-215674
json_url
https://secwatch.observer/filing/0001193125-26-215674.json
markdown_url
https://secwatch.observer/filing/0001193125-26-215674.md
text_url
https://secwatch.observer/filing/0001193125-26-215674.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1907108/000119312526215674/0001193125-26-215674-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1907108/000119312526215674/lxeo-20260511.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

c0dec8379e317f2ca7512f0e23718151b78bfbab

Lexeo Therapeutics, Inc. reported the first quarter 2026 results: net income Net loss was $20.2 million or $0.25 per share (basic and diluted) for the three months ended March 31, 2026, EPS $0.25 per share (basic and diluted).

Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

SEC 8-K Item 2.02 confidence 0.9 SEC evidence

Comparable filings

SNDA

Sonida Senior Living reports Q1 net loss of $41.2M; revenue up 37% on CHP acquisition

SONIDA SENIOR LIVING, INC. May 11, 2026, 7:59 PM ET earnings Items 2.02, 8.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 8.01, 9.01 same event type: earnings similar materiality

This filing

Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

Comparable filing

Sonida Senior Living Announces First Quarter 2026 Results DALLAS, Texas – May 11, 2026 – Sonida Senior Living, Inc. (the “Company,” “Sonida,” “we,” “our,” or “us”) (NYSE: SNDA), a leading owner, operator and investor of senior housing communities, today announced its results for the first quarter ended March 31, 2026.

Filing page SEC filing

LQDA

Liquidia Q1 2026 net income $53M vs $38M loss YoY; YUTREPIA sales $130M

Liquidia Corp May 11, 2026, 7:59 PM ET earnings Items 2.02, 8.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 8.01, 9.01 same event type: earnings similar materiality

This filing

Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

Comparable filing

First Quarter 2026 Financial Results YUTREPIA sales led to the company’s third consecutive quarter of profitability with net income of $52.9 million and positive non-GAAP adjusted EBITDA of $71.2 million in the first quarter of 2026. Cash and cash equivalents totaled $222.8 million as of March 31, 2026, compared to $190.7 million as of December 31, 2025. Product sales, net, were $129.9 million for the three months ended March 31, 2026.

Filing page SEC filing

CRON

Cronos Q1 net revenue up 40% to $45.2M; authorizes $50M share buyback; CanAdelaar close extended to Sep 9

Cronos Group Inc. May 11, 2026, 7:59 PM ET earnings Items 1.01, 2.02, 8.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 8.01, 9.01 same event type: earnings similar materiality

This filing

Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

Comparable filing

reference in such a filing or document. --- EX-99.1 (EX-99.1) --- Cronos Group Reports 2026 First Quarter Results Net revenue in Q1 2026 increased by 40% year-over-year to $45.2 million Achieved record net revenue and gross profit in Q1 2026 Reached #1 market share in vapes in Canada 1 Ninth consecutive quarter of record net revenue in Israel, where PEACE

Filing page SEC filing

CERT

Certara Q1 revenue $106.9M (+1%), net loss $8.8M; divests Regulatory Writing for $85M cash

Certara, Inc. May 11, 2026, 7:59 PM ET earnings Items 2.02, 8.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 8.01, 9.01 same event type: earnings similar materiality

This filing

Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

Comparable filing

First Quarter 2026 Results Total revenue for the first quarter of 2026 was $106.9 million, representing year-over-year growth of 1% on a reported basis. Software revenue for the first quarter of 2026 was $49.7 million, representing year-over-year growth of 7% on a reported basis. Services revenue for the first quarter of 2026 was $57.2 million, representing a year-over-year decrease of 4% on a reported basis . Total Bookings for the first quarter of 2026 were $115.3 million, representing a year-over-year decrease of 2%. Software Bookings for the first quarter of 2026 were $48.7 million, representing a year-over-year increase of 20%. The increase in software bookings was attributable to strong customer demand across our platform. Services Bookings for the first quarter of 2026 were $66.6 million, representing a year-over-year decrease of 14%. The decrease in services bookings was primarily driven by the timing of contract recognition and execution. Total cost of revenues for the first q

Filing page SEC filing

CRCL

Circle Q1 revenue +20% to $694M; announces $222M ARC token presale

Circle Internet Group, Inc. May 11, 2026, 7:59 PM ET earnings Items 2.02, 8.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 8.01, 9.01 same event type: earnings similar materiality

This filing

Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

Comparable filing

USDC in circulation of $77.0 billion at quarter end grew 28%; USDC onchain transaction volume in Q1’26 of $21.5 trillion grew 263% ● Total revenue and reserve income in Q1’26 of $694 million grew 20% ● Net income from continuing operations in Q1’26 of $55 million decreased 15% ● Adjusted EBITDA in Q1’26 of $151 million grew 24% Business Highlights ● ARC Token: $222M

Filing page SEC filing

ASIX

AdvanSix Q1 net loss $15.5M; sales up 7% to $404M; declares $0.16 dividend; appoints new CFO

AdvanSix Inc. May 8, 2026, 7:59 PM ET earnings Items 2.02, 8.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 8.01, 9.01 same event type: earnings similar materiality

This filing

Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

Comparable filing

the second quarter." Summary first quarter 2026 financial results for the Company are included below: 1 ( $ in Thousands, Except Earnings Per Share) 1Q 2026 1Q 2025 (1) Sales $404,183 $377,791 Net Income (loss) (15,546) 23,344 Diluted Earnings Per Share (0.58) 0.86 Adjusted Diluted Earnings Per Share (2) (0.50) 0.93 Adjusted EBITDA (2) 4,756 51,626 Adjusted

Filing page SEC filing

GMRS

GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B

GMR Solutions Inc. June 1, 2026, 4:45 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

Comparable filing

today announced financial results for the first quarter ended March 31, 2026, and full year 2026 financial guidance. First Quarter 2026 Financial Highlights ● Net revenue of $1,457.6 million, up 6.6% compared to $1,367.4 million in the first quarter of 2025 ● Net income of $106.3 million, up 179.7% compared to $38.0 million in the first quarter of 2025 ● Adjusted

Filing page SEC filing

CRDO

Credo Q4 revenue $437M (+157% YoY); guides Q1 $465-475M; CEO awarded 1.44M performance-based RSUs

Credo Technology Group Holding Ltd June 1, 2026, 4:08 PM ET earnings Items 2.02, 5.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

Comparable filing

On June 1, 2026, Credo Technology Group Holding Ltd (the "Company") issued a press release announcing its financial results for the fiscal year ended May 2, 2026.

Filing page SEC filing

Source: SEC EDGAR
accession 0001193125-26-215674
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.